All articles

Foundayo Dosing: Which Strength Is Right For You?

Foundayo Dosing: Which Strength Is Right For You?


Written by:

Dr. Zoë Lees (PhD)

Medically reviewed by:

Dr. Sophie Dix (BSc, PhD)

Published:

17 August 2026

Reading time: 6 minutes
Foundayo Dosing: Which Strength Is Right For You?

Thinking about starting Foundayo? Here’s everything you need to know about this new oral weight loss medication, including how much to take and when.

Article Summary:

  • Foundayo (orforglipron) is a once-daily oral GLP-1 (glucagon-like peptide-1) receptor agonist developed to help with weight management in people with obesity.
  • Foundayo has a different molecular structure to other oral weight loss medications like Wegovy Pill, which means you can take it at any time of day, with or without food.
  • It’s important to know which weight loss treatment suits your lifestyle and speak to a healthcare professional for support.

What is Foundayo?

Foundayo is a prescription-only GLP-1 weight loss tablet that contains the active ingredient orforglipron. In April 2026, it was approved in the USA by the Food and Drug Administration (FDA) as a once-daily tablet alternative to injectable GLP-1 medicines for the treatment of obesity, and was later approved by the UK’s medicine regulator, Medicines and Healthcare Products Regulatory Agency (MHRA) in August 2026.

It’s a once-daily tablet with no timing or fasting requirements, which could make it a practical alternative to Wegovy Pill, or GLP-1 injectables such as Mounjaro for anyone who:

  • Finds it difficult to stick to a fixed routine (such as shift workers or frequent travellers)
  • Would rather not use an injectable pen or needles
  • Wants a treatment they can take with or without food

How does Foundayo work?

Orforlipron, the active ingredient in Foundayo, works by mimicking GLP-1, a hormone your body naturally produces after eating. This helps reduce appetite, delays gastric emptying (this means it slows the rate at which food leaves your stomach) and helps you feel fuller for longer, making it easier to eat less.

Foundayo's approval is based on a trial called ATTAIN-1. Adults with obesity took one of three doses of orforglipron, or a placebo, for 72 weeks (1 year, 5 months). At the highest dose, people lost an average of 12.4% of their body weight, compared with 2.1% on placebo. [1] For someone who weighs 100kg, that works out at around 12.4kg on average in 1 year and 5 months.

Similar to other GLP-1 treatments, Foundayo is designed to be used alongside a reduced-calorie diet and regular physical activity.

Foundayo dosage guide

Once it’s available in the UK, Foundayo can be provided in 6 doses, ranging from 0.8mg-17.2mg (0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg and 17.2mg).

If you're new to GLP-1 treatments, you'll always start on the lowest strength of Foundayo. This gives your body time to adjust to the medication and helps reduce the likelihood of side effects. Your clinician may gradually increase your dose over time if needed, based on how well you're responding to treatment, how well you tolerate it, and what you hope to achieve. This is a process known as titration.

It can take 5 months to reach the highest dose of Foundayo. Not everyone will need to reach the highest dose. The most important factor is finding the dose that is most comfortable, and therefore most sustainable for you.

Here’s an example of how your journey could look, depending on how your side effects feel, or how much weight you lose.

Foundayo Dosage Table

MonthDose StrengthStage
Month 10.8mgLowest strenght
Month 22.5mgFirst dose increase
Month 35.5mgMaintenance
Month 4+9mg, 14.5mg, or 17.2mgHigher strengths and maintenance

How do I take the Foundayo weight loss pill?

  • Swallow it whole, with water. Don’t break, crush or chew the tablet
  • Take it with or without food. No fasting needed.
  • Only take one per day. Try to aim for the same time.

Why choose Foundayo?

Foundayo is the only GLP-1 weight loss tablet you can take at any time of day, with any food or drink, and with no fasting requirements before or after. There’s no strict morning routine to protect, no 30-minute window to plan around, and no need to time it alongside your other medications.

For people whose lives don't fit neatly around a fixed morning routine, that flexibility could be the difference between a treatment that works for your life and one that doesn't. Foundayo is also completely injection-free. There are no needles, no injection sites and no refrigeration.

Convenience is typically a great benefit to most oral weight loss treatments, however, it’s important to consider your medical history, any medications you are taking, overall health and the results you’d like during your weight management journey.

Is Foundayo the oral version of Mounjaro?

In short, no. This is a common misconception as both Foundayo and Mounjaro are made by the same parent company, Eli Lilly and Company. Mounjaro contains tirzepatide, which mimics two hormones (GLP-1 and GIP), and the orforglipron in Foundayo mimics only one hormone (GLP-1).

If you’re thinking about switching from Mounjaro to Foundayo for weight loss when you’re still actively trying to lose weight, it’s important to know that this may delay your progress, and could even cause your body weight to increase instead of supporting weight reduction. [2]

Foundayo may be more suitable for you if you’ve already (or almost) reached your goal weight and you’re looking for ways to maintain your results. To know more about switching, speak to our experts or your current provider.

What are the side effects of Foundayo?

Foundayo causes similar side effects to other weight loss medications, including those that are injected. Reported side effects tend to be gastrointestinal (related to your stomach) and include:

  • Feeling or being sick (nausea)
  • Diarrhoea
  • Constipation
  • Indigestion or stomach pain
  • Headache
  • Tiredness (fatigue)
  • Bloating
  • Burping or wind

These are usually more noticeable when you start treatment or when your dose goes up.

If you experience any of these symptoms, particularly stomach upset like nausea or constipation, you can find advice on how to ease them in our dedicated Side Effects Guide.

Foundayo also carries a warning about a possible risk of thyroid tumours, and isn’t suitable if you or a family member has had certain types of thyroid cancer. Uncommonly, it can also cause pancreatitis, low blood sugar, or allergic reactions.

Can I use Foundayo during pregnancy?

If you can become pregnant, it is important to use contraception while taking Foundayo. Barrier contraception, such as condoms, is recommended while taking Foundayo and for 4 weeks after each dose increase. This is because Foundayo may affect how well oral contraceptives work. It's not suitable to take Foundayo during pregnancy, while trying to become pregnant, or breastfeeding. It's not advised to use any method of weight reduction or obesity treatment to change your body weight during pregnancy, as it could cause fetal harm.

It’s important to us that you get your dosing schedule right because it’s key to managing your weight loss journey safely and effectively. At MedExpress, we offer online consultations with regular clinical check-ins, and a range of weight loss treatments including Mounjaro Pen, Wegovy Pen, Wegovy Pill and Foundayo (coming soon, join the waitlist) and our team can help you find the right treatment for you.

References

  1. Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056/NEJMoa2511774. Epub 2025 Sep 16. PMID: 40960239.
  2. Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine [Internet]. 2026 May 13 [cited 2026 Aug 12];. Available from: https://www.nature.com/articles/s41591-026-04386-7

Next scheduled review date: 17 August 2029

Authors

Dr. Zoë Lees, PhD Metabolic Medicine

Written by: Dr. Zoë Lees (PhD)

Dr. Zoë Lees is a medical writer at MedExpress specialising in obesity and health communication. She completed her PhD at the University of Glasgow, where she investigated adipose tissue (fat tissue) function in pregnancies complicated by pre-eclampsia and gestational diabetes. Her work focuses on translating complex clinical evidence into clear, engaging and evidence-based health information for patients and the public. At MedExpress, Zoë contributes to clinical content, educational resources and media communications across areas including weight management, GLP-1 therapies and metabolic disease. Zoë is particularly interested in improving public understanding of obesity as a chronic condition and ensuring patients have access to accurate, accessible health information grounded in current scientific evidence.

Dr. Sophie Dix

Medically reviewed by: Dr. Sophie Dix (BSc, PhD)

Dr. Sophie Dix is Head of Medical Affairs at MedExpress. A behavioural neuroscientist by training, Sophie has spent 30 years working at the intersection of medical research, pharmacology, technology and patient communication across the pharmaceutical industry, health technology and charity sectors. At MedExpress, Sophie's role is to ensure that everything the organisation does is grounded in the most current science. That means translating complex clinical evidence into accessible health information across the website, clinical pathways and media communications. It also means working with external press and broadcast media as a named expert commentator, making the science behind weight management and GLP-1 treatments understandable to a general audience. A core part of Sophie's work is building MedExpress's Real-World Evidence (RWE) programme: learning systematically from patient outcomes to understand what works in practice, not just in clinical trials. This patient-level insight feeds directly into improving patient experience and health outcomes. Sophie believes that patients make better decisions when they have access to accurate, evidence-based information. As an advocate for meaningful change in how obesity is understood, Sophie works to reduce stigma and raise awareness of the condition as an illness. This includes reframing the conversation around GLP-1s from aesthetics to public health, while highlighting the health benefits of weight loss and weight management.

Note from the experts

Remember: This blog shouldn’t be regarded as medical advice, diagnosis, or treatment. We make sure everything we publish is fact checked by clinical experts and regularly reviewed, but it may not always reflect the most recent health guidelines. Always speak to your doctor about any health concerns you have.